Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for ...

Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and ...

Many drugs use active ingredients that are manufactured outside the U.S., among them the anticoagulant heparin, which 12 million patients use each year. Meanwhile, AstraZeneca's Chairman Michel Demaré ...

Haleon PLC closed 10.34% below its 52-week high of £4.18, which the company achieved on March 4th.

Investing.com -- Moody's Ratings has upgraded the long-term issuer rating of Haleon plc and its guaranteed subsidiaries to A3 from Baa1. The rating agency also upgraded the rating on Haleon's ...

Haleon plc (LSE/NYSE:HLN), a global leader in consumer health with a market capitalization of $43 billion, reported on Monday that two of its top executives have participated in the company’s ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...